Home > Healthcare > Medical Devices > Therapeutic Devices > Tubeless Insulin Pump Market
Tubeless Insulin Pump Market size was valued at around USD 1.6 billion in 2022 and is projected to reach over USD 8.9 billion by 2032. The increasing prevalence of diabetes is a significant driver for the market.
According to the International Diabetes Federation (IDF), in 2021, the global population having diabetes mellitus (DM) was estimated to be 463 million in 2019 and is going to increase to 700 million by 2045. The increasing number of diabetes cases around the globe can be attributable to factors such as genetics, aging population, and lifestyle among others. Moreover, the ongoing technological advancements along with incremental healthcare expenditure associated with diabetes are further contributing to the market progress.
Tubeless insulin pump refers to a medical device designed to help manage diabetes by delivering a continuous supply of insulin to a patient's body without the need for traditional insulin injections. Tubeless insulin pumps are designed to be worn directly on the body and do not have external tubing.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Tubeless Insulin Pump Market Size in 2022: | USD 1.6 Billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 19.2% |
2032 Value Projection: | USD 8.9 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 100 |
Tables, Charts & Figures: | 70 |
Segments covered: | End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
However, the high cost associated with advanced tubeless insulin pumps can cause a challenge and hinder market growth in the projected timeframe. For instance, the cost of an adult insulin delivery system ranges between USD 4,500 to USD 6,500 and may vary according to the technology and sensors used in these devices. The high cost of these devices may limit acceptance by the diabetic population, affecting manufacturers’ ability to invest in the technology. Thus, the aforementioned factors are anticipated to impede the market expansion.
The COVID-19 pandemic had a slightly negative impact on the growth of the tubeless insulin pump market in the initial quarter of 2020. However, the subsequent three quarters of the year experienced a positive impact, ultimately offsetting the initial negative effect and consequently contributing to positive market demand.
Rising technological advancements in insulin delivery devices intended to improve the comfort, safety, and overall well-being of individuals suffering from diabetes that will spur business growth. Modern tubeless insulin pumps come equipped with unique features such as advanced algorithms, an integrated continuous glucose monitoring (CGM) system, and bluetooth connectivity among others. The integration of a continuous glucose monitoring system allows users to monitor their blood glucose levels continuously and provide more accurate insulin delivery adjustments in real time, reducing the risk of hypoglycemia and hyperglycemia.
The homecare segment accounted for USD 1.2 billion in 2022 and is set to witness notable growth in the coming years. This significant share is majorly attributed to the surging adoption of tubeless insulin pumps in home care settings. The surged pressure to limit the heightened healthcare expenses concerning diabetes management, notable developments, and access of these easy-to-use diabetes care devices is anticipated to drive the market size.
The North America tubeless insulin pump market is projected to reach USD 5.5 billion by 2032. This significant market growth is majorly attributed to the facilitative reimbursement scenario, the high prevalence of diabetes, and the presence of major market players in the region.
The tubeless insulin pump industry is consolidated in nature, with major companies competing to offer superior tubeless insulin pumps in this business space. Prominent players such as Insulet Corporation hold a significant company market share. These companies are diligently directing their efforts towards continuous product innovation to gain substantial market share. For instance, Insulet Corporation announced the U.S. FDA approval of the Omnipod DASH Insulin Management System with a tubeless pump, bluetooth connectivity, and personal diabetes manager. This enables quick access to insulin therapy information to patients as well as professionals on their smartphones.
Some of the major market players operating in the tubeless insulin pump industry are:
Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company expansion.
Click here to Buy Section of this Report
By End-use, 2018 - 2032 (USD Million)
The above information is provided for the following regions and countries: